Saniona AB
STO:SANION

Watchlist Manager
Saniona AB Logo
Saniona AB
STO:SANION
Watchlist
Price: 8.12 SEK 0.62% Market Closed
Market Cap: 903.3m SEK
Have any thoughts about
Saniona AB?
Write Note

Saniona AB
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Saniona AB
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Saniona AB
STO:SANION
Interest Income Expense
-kr21.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genmab A/S
CSE:GMAB
Interest Income Expense
kr1.6B
CAGR 3-Years
643%
CAGR 5-Years
53%
CAGR 10-Years
65%
Zealand Pharma A/S
CSE:ZEAL
Interest Income Expense
kr119.1m
CAGR 3-Years
N/A
CAGR 5-Years
36%
CAGR 10-Years
45%
Ascendis Pharma A/S
NASDAQ:ASND
Interest Income Expense
-€101.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bavarian Nordic A/S
CSE:BAVA
Interest Income Expense
kr93.2m
CAGR 3-Years
N/A
CAGR 5-Years
56%
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Interest Income Expense
kr558k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Saniona AB
Glance View

Market Cap
903.3m SEK
Industry
Biotechnology

Saniona AB engages in the research and development on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases, and treatment of pain. The company operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The firm develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The firm is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.

SANION Intrinsic Value
3.56 SEK
Overvaluation 56%
Intrinsic Value
Price

See Also

What is Saniona AB's Interest Income Expense?
Interest Income Expense
-21.9m SEK

Based on the financial report for Jun 30, 2024, Saniona AB's Interest Income Expense amounts to -21.9m SEK.

What is Saniona AB's Interest Income Expense growth rate?
Interest Income Expense CAGR 1Y
21%

Over the last year, the Interest Income Expense growth was 21%.

Back to Top